# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0165 |
| PP ID | PP-0165 |
| Title | Atrophic Gastritis and Gastric Cancer |
| Version | 1.0.0 |
| Status | PASS — GOLD |

# Layer 1 — Content QA

| Criterion | Result |
|---|---|
| Atomic clinical question | PASS |
| Approved PP identity | PASS |
| Full-depth CKO structure | PASS |
| Full-depth Knowledge Passport | PASS |
| Full-depth Evidence Package | PASS |
| Independent knowledge blocks | PASS |
| Patient explanations present | PASS |
| Clinical importance present | PASS |
| Key concepts present | PASS |
| Common misconceptions present | PASS |
| Key messages present | PASS |
| Knowledge Graph present | PASS |
| Revision history present | PASS |
| Scope and exclusions explicit | PASS |

# Layer 2 — Clinical QA

| Criterion | Result |
|---|---|
| Source-first clinical content | PASS |
| NCI risk/precursor terminology preserved | PASS |
| H. pylori pathway correctly represented | PASS |
| Autoimmune pathway correctly represented | PASS |
| Atrophy distinguished from cancer | PASS |
| Risk distinguished from inevitability | PASS |
| Intestinal metaplasia distinguished from atrophy | PASS |
| Dysplasia kept downstream | PASS |
| Pernicious-anemia relationship correctly bounded | PASS |
| Pepsinogen limitations preserved | PASS |
| No universal pepsinogen cutoff invented | PASS |
| No universal screening interval invented | PASS |
| No individualized absolute-risk claim | PASS |
| H. pylori eradication not overextended | PASS |
| Treatment advice excluded | PASS |

# Layer 3 — Educational QA

| Criterion | Result |
|---|---|
| Plain-language writing | PASS |
| Medical terminology explained | PASS |
| One major concept per knowledge block | PASS |
| Patient-centered framing | PASS |
| Neutral tone | PASS |
| No alarmist language | PASS |
| Uncertainty visible | PASS |
| Misconceptions addressed | PASS |
| Risk not framed as diagnosis | PASS |
| Downstream routing clear | PASS |

# Layer 4 — Governance QA

| Criterion | Result |
|---|---|
| Source-First rule | PASS |
| CORE_WORKING_RULES v1.6 compliance | PASS |
| FREEZE GOLD specification compliance | PASS |
| Approved Decision Batch basis | PASS |
| Gold artifact architecture preserved | PASS |
| Full-depth / non-compacted rule | PASS |
| Adjacent PP overlap checked | PASS |
| Boundary declared cleanly | PASS |
| Knowledge Graph linkage | PASS |
| Evidence traceability | PASS |
| Four artifacts complete | PASS |
| ZIP package complete | PASS |
| Semantic versioning | PASS |
| Repository-ready structure | PASS |

# Full-Depth Compliance Check

This production intentionally preserves the project's Gold depth standard.

The CKO contains a granular knowledge architecture rather than a compact summary. Each block separates:

1. Patient Explanation;
2. Clinical Importance;
3. Key Concepts.

The Knowledge Passport separately records identity, classification, journey, runtime use, retrieval relevance, graph, scope, sources, evidence classification, governance and versioning.

The Evidence Package separately records the clinical question, evidence hierarchy, evidence matrix, evidence notes, claims summary, consistency review, gaps, delegation, update triggers, traceability and boundary verification.

The QA artifact independently evaluates content, clinical, educational and governance layers.

The package is therefore **not a compacted four-file summary**.

# Boundary QA

**Boundary: Core = definition of atrophic gastritis, chronic gastric mucosal atrophy, H. pylori-associated and autoimmune pathways, increased gastric-cancer risk, Correa's cascade, relationship with intestinal metaplasia and dysplasia, distinction between risk and inevitable cancer, and clinical significance of recognizing atrophic gastritis; Supporting = pernicious anemia/B12 malabsorption, conceptual diagnostic recognition, serum pepsinogen as a limited marker, screening/follow-up context, and high-level gastric-cancer subtype context; Explicitly Excluded = H. pylori testing/eradication, detailed autoimmune work-up/treatment, detailed B12 replacement, detailed intestinal-metaplasia classification/surveillance, gastric-cancer screening algorithms, pepsinogen decision algorithms, dysplasia treatment, gastric adenoma management, hereditary gastric-cancer genetics, gastric-cancer treatment, post-gastrectomy nutrition, and individualized gastric-cancer risk calculation; Delegated-to PP = PP-0012, PP-0160, PP-0161, PP-0166, PP-0167, PP-0170, Endoscopy, Biopsy, Dysplasia/precursor-lesion management, Hereditary Gastric Cancer, Gastric Cancer Treatment.**

# Architecture QA

PP-0165 remains an atomic risk/precursor-condition package.

It does not absorb:

- H. pylori testing/eradication;
- intestinal-metaplasia ownership;
- pernicious-anemia management;
- screening algorithms;
- pepsinogen screening algorithms;
- dysplasia management;
- hereditary gastric-cancer management;
- gastric-cancer treatment.

# Final QA Decision

## PASS

All four Gold artifacts are complete, source-grounded, non-compacted, and aligned with the locked PP-0165 scope and adjacent-package ownership.

# QA Final Status

**PASS — GOLD — READY FOR INTEGRATION.**
